Ads
related to: sorafenib fda approval- Mechanism of Action
Visit To Learn More About
The Mechanism of Action.
- Co-Pay Program
Learn About A $0 Co-Pay Program
For Eligible CABOMETYX® Patients.
- Prescribing Information
Download The Prescribing
Information For CABOMETYX®.
- Contact A Rep
Contact A Representative To Find
Additional Information.
- Mechanism of Action
Search results
Results From The WOW.Com Content Network
Sorafenib, sold under the brand name Nexavar, [3] is a kinase inhibitor drug approved for the treatment of primary kidney cancer (advanced renal cell carcinoma), advanced primary liver cancer (hepatocellular carcinoma), FLT3-ITD positive AML and radioactive iodine resistant advanced thyroid carcinoma.
FDA has approved three drugs, bevacizumab, sunitinib and sorafenib, that were developed for antiangiogenic actions and are used in the treatment of patients with specific cancer types. All of these drugs have the mechanism of inhibiting VEGF signalling by blocking either the function of the VEGF ligand or VEGF receptor.
Sorafenib, co-developed and co-marketed with Bayer and sold under the trade name Nexavar, is a drug approved in the United States for the treatment of advanced renal cell carcinoma (kidney cancer) in 2005, and for the treatment of inoperable hepatocellular carcinoma, the most common form of liver cancer, in 2007.
Amgen's cancer drug Nexavar is going to reach a broader market. Today, the Food and Drug Administration widened its approval for the drug to include its use in the treatment of several forms of ...
Merck (MRK) and Japanese partner Eisai gain an approval from the EU for Lenvima label expansion. The anti-cancer drug receives the regulatory body's nod for first-line treatment of unresectable HCC.
In 2007, sorafenib, an oral multikinase inhibitor, was the first systemic agent approved for first-line treatment of advanced HCC. [75] Trials have found modest improvement in overall survival: 10.7 months vs 7.9 months and 6.5 months vs 4.2 months. [76] [75] The most common side effects of Sorafenib include a hand-foot skin reaction and ...